Targeted metabolomics assays are now widely adopted for large-scale profiling in clinical studies, but their analytical validation has focused almost exclusively on standard biofluids such as plasma and serum. Adapting these platforms to minimally invasive sampling approaches, including dried blood spots (DBS), remains an underexplored challenge that demands specific optimization and validation efforts. In this study, we optimized and characterized the TMIC MTX MEGA assay for DBS samples (Whatman 903), following a structured analytical pipeline that included metabolite coverage assessment, cross-matrix comparison, and evaluation of longitudinal performance. The platform integrates reverse-phase LC-MS/MS with direct flow-injection mass spectrometry, allowing simultaneous quantification of metabolites spanning several chemical classes. For validation purposes, we used paired DBS and serum samples obtained from 11 subjects enrolled in a cardiac rehabilitation program, collected at two separate time points. Quantification yielded 323 metabolites in DBS versus 496 in serum. Principal component analysis revealed a clear separation between the two matrices, consistent with known biological and pre-analytical factors. The absence of some metabolites or lower yields for some classes in DBS were linked to matrix-related biological factors or intrinsic limitations of the analytical panel. Although absolute concentration levels differed between matrices, both Pearson correlation and paired t-tests (p < 0.05) indicated robust conservation of longitudinal metabolic trends, at both the class and individual participant level. Notable exceptions emerged for triacylglycerols and metabolites of predominantly intracellular origin, likely reflecting a combination of analytical and biological factors. Overall, this study establishes a reproducible strategy for translating the TMIC MTX MEGA assay to DBS samples while maintaining detection of longitudinal metabolic changes. These findings support the feasibility of DBS as a minimally invasive tool for longitudinal metabolic monitoring, paving the way for its broader application in large-scale targeted metabolomics research.

Bossi, E., Prehn, C., Crotti, L., Malfatto, G., Paglia, G., Witting, M. (2026). Bridging the matrix gap: a targeted metabolomics assay workflow optimization for dried blood spots analysis. Intervento presentato a: EMN & Affiliates Virtual Symposium, Online Conference.

Bridging the matrix gap: a targeted metabolomics assay workflow optimization for dried blood spots analysis

Bossi, E
Primo
;
Crotti, L;Paglia, G;
2026

Abstract

Targeted metabolomics assays are now widely adopted for large-scale profiling in clinical studies, but their analytical validation has focused almost exclusively on standard biofluids such as plasma and serum. Adapting these platforms to minimally invasive sampling approaches, including dried blood spots (DBS), remains an underexplored challenge that demands specific optimization and validation efforts. In this study, we optimized and characterized the TMIC MTX MEGA assay for DBS samples (Whatman 903), following a structured analytical pipeline that included metabolite coverage assessment, cross-matrix comparison, and evaluation of longitudinal performance. The platform integrates reverse-phase LC-MS/MS with direct flow-injection mass spectrometry, allowing simultaneous quantification of metabolites spanning several chemical classes. For validation purposes, we used paired DBS and serum samples obtained from 11 subjects enrolled in a cardiac rehabilitation program, collected at two separate time points. Quantification yielded 323 metabolites in DBS versus 496 in serum. Principal component analysis revealed a clear separation between the two matrices, consistent with known biological and pre-analytical factors. The absence of some metabolites or lower yields for some classes in DBS were linked to matrix-related biological factors or intrinsic limitations of the analytical panel. Although absolute concentration levels differed between matrices, both Pearson correlation and paired t-tests (p < 0.05) indicated robust conservation of longitudinal metabolic trends, at both the class and individual participant level. Notable exceptions emerged for triacylglycerols and metabolites of predominantly intracellular origin, likely reflecting a combination of analytical and biological factors. Overall, this study establishes a reproducible strategy for translating the TMIC MTX MEGA assay to DBS samples while maintaining detection of longitudinal metabolic changes. These findings support the feasibility of DBS as a minimally invasive tool for longitudinal metabolic monitoring, paving the way for its broader application in large-scale targeted metabolomics research.
abstract + slide
Targeted Metabolomics, Dried Blood Spots, Method Optimization, LC-MS/MS
English
EMN & Affiliates Virtual Symposium
2026
2026
none
Bossi, E., Prehn, C., Crotti, L., Malfatto, G., Paglia, G., Witting, M. (2026). Bridging the matrix gap: a targeted metabolomics assay workflow optimization for dried blood spots analysis. Intervento presentato a: EMN & Affiliates Virtual Symposium, Online Conference.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/630521
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
Social impact